Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium PressReach · Dec 1, 2022
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients PressReach · Dec 1, 2022
Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI® PressReach · Dec 1, 2022
Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement PressReach · Dec 1, 2022
Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types PressReach · Dec 1, 2022
Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress PressReach · Dec 1, 2022
ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE PressReach · Nov 30, 2022
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference PressReach · Nov 30, 2022
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development PressReach · Nov 30, 2022
Cosmos Health Enters the Development Phase for CCX0722, an Innovative Product for Obesity and Weight Management PressReach · Nov 30, 2022